Class information for:
Level 1: PARP INHIBITORS//OLAPARIB//SYNTHETIC LETHALITY

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
10345 1071 48.7 89%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
512 3       BRCA1//BRCA2//FANCONI ANEMIA 21435
900 2             BRCA1//BRCA2//FANCONI ANEMIA 11301
10345 1                   PARP INHIBITORS//OLAPARIB//SYNTHETIC LETHALITY 1071

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PARP INHIBITORS authKW 2366212 15% 50% 165
2 OLAPARIB authKW 1742575 7% 79% 77
3 SYNTHETIC LETHALITY authKW 504987 6% 26% 68
4 VELIPARIB authKW 502901 2% 84% 21
5 BRCANESS authKW 369473 2% 72% 18
6 ABT 888 authKW 364915 1% 80% 16
7 RUCAPARIB authKW 287469 1% 92% 11
8 PARP INHIBITION authKW 228052 2% 40% 20
9 HOMOLOGOUS RECOMBINATION DEFICIENCY authKW 209930 1% 82% 9
10 PARP1 authKW 179383 3% 21% 30

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 16531 63% 0% 680
2 Cell Biology 498 13% 0% 137
3 Chemistry, Medicinal 246 5% 0% 56
4 Pharmacology & Pharmacy 234 11% 0% 119
5 Obstetrics & Gynecology 121 4% 0% 43
6 Biochemistry & Molecular Biology 51 11% 0% 114
7 Medicine, Research & Experimental 45 4% 0% 39
8 Genetics & Heredity 33 4% 0% 41
9 Pathology 27 2% 0% 23
10 Radiology, Nuclear Medicine & Medical Imaging 15 3% 0% 30

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DNA THER EUT 114038 0% 100% 4
2 CRUK GENE FUNCT 96023 1% 42% 8
3 MED ONCOLMED GYNECOL ONCOL PROGRAM 91229 0% 80% 4
4 BREAKTHROUGH BREAST CANC 82864 4% 6% 45
5 EXPT PRECLIN 64145 0% 75% 3
6 DRUG DEV UNIT 50665 2% 9% 19
7 CLIN TARGET VALIDAT 48161 1% 24% 7
8 PL DEV SUPPORT DIRECTORATE 47509 0% 33% 5
9 NO CANC 44182 3% 5% 29
10 BCOH EA4340 38011 0% 67% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MOLECULAR CANCER THERAPEUTICS 8060 3% 1% 34
2 CLINICAL CANCER RESEARCH 8060 6% 0% 65
3 CANCER DISCOVERY 5003 1% 2% 9
4 HEREDITARY CANCER IN CLINICAL PRACTICE 3906 0% 3% 5
5 NATURE REVIEWS CLINICAL ONCOLOGY 3147 1% 2% 7
6 MOLECULAR CANCER RESEARCH 2559 1% 1% 13
7 ONCOTARGET 2334 3% 0% 32
8 BREAST CANCER RESEARCH 1870 1% 1% 12
9 ANNALS OF ONCOLOGY 1799 2% 0% 23
10 NATURE REVIEWS CANCER 1693 1% 1% 8

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 PARP INHIBITORS 2366212 15% 50% 165 Search PARP+INHIBITORS Search PARP+INHIBITORS
2 OLAPARIB 1742575 7% 79% 77 Search OLAPARIB Search OLAPARIB
3 SYNTHETIC LETHALITY 504987 6% 26% 68 Search SYNTHETIC+LETHALITY Search SYNTHETIC+LETHALITY
4 VELIPARIB 502901 2% 84% 21 Search VELIPARIB Search VELIPARIB
5 BRCANESS 369473 2% 72% 18 Search BRCANESS Search BRCANESS
6 ABT 888 364915 1% 80% 16 Search ABT+888 Search ABT+888
7 RUCAPARIB 287469 1% 92% 11 Search RUCAPARIB Search RUCAPARIB
8 PARP INHIBITION 228052 2% 40% 20 Search PARP+INHIBITION Search PARP+INHIBITION
9 HOMOLOGOUS RECOMBINATION DEFICIENCY 209930 1% 82% 9 Search HOMOLOGOUS+RECOMBINATION+DEFICIENCY Search HOMOLOGOUS+RECOMBINATION+DEFICIENCY
10 PARP1 179383 3% 21% 30 Search PARP1 Search PARP1

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 LORD, CJ , ASHWORTH, A , (2016) BRCANESS REVISITED.NATURE REVIEWS CANCER. VOL. 16. ISSUE 2. P. 110 -120 53 58% 23
2 WANG, YQ , WANG, PY , WANG, YT , YANG, GF , ZHANG, A , MIAO, ZH , (2016) AN UPDATE ON POLY(ADP-RIBOSE)POLYMERASE-1 (PARP-1) INHIBITORS: OPPORTUNITIES AND CHALLENGES IN CANCER THERAPY.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 59. ISSUE 21. P. 9575 -9598 102 66% 0
3 WAGNER, LM , (2015) PROFILE OF VELIPARIB AND ITS POTENTIAL IN THE TREATMENT OF SOLID TUMORS.ONCOTARGETS AND THERAPY. VOL. 8. ISSUE . P. 1931 -1939 51 98% 13
4 SONNENBLICK, A , DE AZAMBUJA, E , AZIM, HA , PICCART, M , (2015) AN UPDATE ON PARP INHIBITORS-MOVING TO THE ADJUVANT SETTING.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 12. ISSUE 1. P. 27 -41 45 67% 64
5 LIVRAGHI, L , GARBER, JE , (2015) PARP INHIBITORS IN THE MANAGEMENT OF BREAST CANCER: CURRENT DATA AND FUTURE PROSPECTS.BMC MEDICINE. VOL. 13. ISSUE . P. - 60 67% 21
6 LUPO, B , TRUSOLINO, L , (2014) INHIBITION OF POLY(ADP-RIBOSYL)ATION IN CANCER: OLD AND NEW PARADIGMS REVISITED.BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. VOL. 1846. ISSUE 1. P. 201 -215 88 47% 30
7 LORD, CJ , TUTT, ANJ , ASHWORTH, A , (2015) SYNTHETIC LETHALITY AND CANCER THERAPY: LESSONS LEARNED FROM THE DEVELOPMENT OF PARP INHIBITORS.ANNUAL REVIEW OF MEDICINE, VOL 66. VOL. 66. ISSUE . P. 455 -470 44 62% 53
8 DEEKS, ED , (2015) OLAPARIB: FIRST GLOBAL APPROVAL.DRUGS. VOL. 75. ISSUE 2. P. 231 -240 34 97% 25
9 SCOTT, CL , SWISHER, EM , KAUFMANN, SH , (2015) POLY (ADP-RIBOSE) POLYMERASE INHIBITORS: RECENT ADVANCES AND FUTURE DEVELOPMENT.JOURNAL OF CLINICAL ONCOLOGY. VOL. 33. ISSUE 12. P. 1397 -+ 61 45% 48
10 NAIPAL, KAT , VAN GENT, DC , (2015) PARP INHIBITORS: THE JOURNEY FROM RESEARCH HYPOTHESIS TO CLINICAL APPROVAL.PERSONALIZED MEDICINE. VOL. 12. ISSUE 2. P. 139 -154 63 66% 1

Classes with closest relation at Level 1


Rank Class id link
1 495 POLYADP RIBOSE POLYMERASE//POLYADP RIBOSE//POLYADP RIBOSYLATION
2 5107 BRCA1//BARD1//BRCA2
3 31664 TANKYRASE//TANKYRASE 1//TANKYRASE INHIBITORS
4 14480 BEVACIZUMAB//OVARIAN CANCER//VEGF TRAP
5 471 BRCA2//BRCA1//HEREDITARY BREAST CANCER
6 28175 CANC UK MRC//REPLICON INITIATION//HYPOXIA REOXYGENATION H R
7 15199 CHEK2//PALB2//CHK2
8 3535 NIJMEGEN BREAKAGE SYNDROME//NBS1//MRE11
9 853 TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE//ONCOTYPE DX
10 15355 BANTING BEST MED//SYNTHETIC DOSAGE LETHALITY//GENETIC INTERACTION

Go to start page